Ungated Post | 06 Mar 2020

Making cells better: Complex challenges drive innovation in cell and gene therapy manufacturing

The processes required for C&GT manufacture are wholly new and extremely complex. As production and delivery of these new therapies to patients are still nascent, biopharmaceutical companies will need to harness new technological advances and innovate continuously in the manufacturing process.

Large capital investments in the industry are likely to bring breakthroughs in the coming years that will standardise processes, simplify delivery logistics, boost efficiency, and increase competition.


Read the full report


Our Thought Leadership team produces original, evidence-based research made accessible to decision-makers and opinion leaders. Principals for this project included:

Oxford Economics’ team is expert at applying advanced economic tools that provide valuable insights into today’s most pressing business, financial, and policy issues.

To find out more about our capabilities, contact:

EMEA
Paul Donnelly
020 3910 8000
Email

Americas
Jeffrey Klonoski
+1 646 503 3048
Email

Asia
Christie Tang
+852 3974 8841
Email

Related Services

Post

Delivering Value: The Economic Impact of the Civil Nuclear Industry

The study suggests the civil nuclear industry supports a £16.1 billion contribution to UK GDP, 211,500 jobs, and £7.1 billion in tax revenues. 24% occurs in the North West and 16% in the South West.

Find Out More

Post

Innovation Index: Are You Prepared to Shift from Survival to Growth?

Oxford Economics and NTT Data fielded a survey of 1,000 North American business and IT executives in 2022 to uncover future strategies to mitigate disruption.

Find Out More

Post

Reinventing for growth in a changing media landscape

Oxford Economics partnered with Accenture to survey 6,000 consumers around the world about their media and entertainment habits, experiences, and preferences.

Find Out More